Cover Image
市場調查報告書

MPS-III (聖菲利柏氏症):主要23個國家的市場預測

Epiomic Epidemiology Series: Mucopolysaccharidosis-III (MPS-III) Sanfilippo Syndrome Forecast in 23 Major Markets 2017-2027

出版商 Black Swan Analysis 商品編碼 436070
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
MPS-III (聖菲利柏氏症):主要23個國家的市場預測 Epiomic Epidemiology Series: Mucopolysaccharidosis-III (MPS-III) Sanfilippo Syndrome Forecast in 23 Major Markets 2017-2027
出版日期: 2017年02月01日 內容資訊: 英文 74 Pages
簡介

本報告提供全球主要主要23個國家的MPS-III (聖菲利柏氏症)的發病情形相關分析,疾病概要和目前的患病人數,各子類型 (A,B,C,D) 及性別、各年代 (5歲區分)的詳細情況,各地區、各民族趨勢,風險要素,疾病診斷與預後,主要的症狀和併發症,未來趨勢預測 (今後10年份) 的資訊彙整,為您概述為以下內容。

目錄

  • 圖表一覽
  • 簡介
  • 疾病的原因
  • 風險要素與預防法
  • 疾病診斷方法
  • 各地區/各民族的差異
  • 疾病的預後和臨床過程
  • 疾病相關的主要的共生病症/特徵
  • 患者數的測量方法
  • MPS-III的最大患病人數
    • 主要的亞型
  • MPS-III患者的特徵
  • 文中的簡稱一覽
  • Black Swan Analysis的其他出版刊物
  • Black Swan Analysis的線上、病患人數的資料庫
  • 病患人數的服務
  • 線上價格資料/平台
  • 參考文獻
  • 附錄

分析觀察對象國家

  • 澳洲、巴西、加拿大、中國、捷克、丹麥、法國、德國、希臘、印度、義大利、日本、荷蘭、挪威、波蘭葡萄牙、俄羅斯、西班牙、瑞典、土耳其、英國、美國、愛沙尼亞

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MPSF0010217

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on MPS-III (Sanfilippo Syndrome) in 23 Major Markets

Mucopolysaccharidosis-III, also known as MPS-III or Sanfilippo syndrome, is part of the Mucopolysaccharidoses (MPS) disorders - a group of rare genetic disorders caused by deficiencies of lysosomal enzymes. These are in-born errors of metabolism, and are autosomal recessive genetic disorders.

There are 4 distinct sub-types of MPS-III (A, B, C & D), with patients ranging from mild to severe in terms of symptoms. Prevalence of the different subtypes varies markedly country to country.

This report provides the current prevalent population for MPS-III across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Australia, Netherlands, Denmark, Sweden, Norway, Turkey, Greece, Portugal, Poland, Estonia, Russia, Czech Republic) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of MPS-III have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for MPS-III disease include:

  • Hernia
  • Hearing loss and otitis
  • Sleep disorders
  • Neurological and behavioural disorders

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global MPS-III market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of MPS-III and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on MPS-III prevalent population.
  • Identify sub-populations within MPS-III which require treatment.
  • Gain an understanding of the specific markets that have the largest number of MPS-III patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line prevalence for MPS-III
    • Main Subtype
  • Features of MPS-III patients
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Prevalence of MPS-III, total (000s)
  • Prevalence of MPS-III, males (000s)
  • Prevalence of MPS-III, females (000s)
  • MPS-III patients by Sub-type, total (000s)
  • MPS-III patients with coarse features, total (000s)
  • MPS-III patients with Hepatomegaly, total (000s)
  • MPS-III patients with language delay, total (000s)
  • MPS-III patients with Abnormal behaviour, total (000s)
  • MPS-III patients with ASD, total (000s)
  • MPS-III patients with epilepsy, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • USA Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Canada Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Canada Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • France Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • France Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Germany Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Germany Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Italy Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Italy Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Spain Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Spain Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • UK Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • UK Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Brazil Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Brazil Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Japan Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Japan Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • India Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • India Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • China Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • China Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Russia Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Russia Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Australia Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Australia Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Netherlands Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Denmark Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Denmark Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Sweden Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Sweden Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Norway Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Norway Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Turkey Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Turkey Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Greece Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Greece Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Portugal Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Portugal Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Poland Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Poland Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Estonia Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Estonia Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Czech Republic Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Czech Republic Prevalence of MPS-III by 5-yr age cohort, females (000s)
Back to Top